{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:58:17Z","timestamp":1777111097709,"version":"3.51.4"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Background: Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings. We then aimed to evaluate the incidence of thromboembolic events and the persistence of edoxaban therapy in the long-term. Methods: In this observational cohort study, we included ischemic stroke patients enrolled in a previous study to evaluate the safety and efficacy of long-term edoxaban treatment. Data were collected by a trained investigator through a structured telephone interview. Results: Sixty-three subjects (median age 81.0 (73.5\u201388.0) years, 38.1% male) were included in the study, with a mean follow-up of 4.4 \u00b1 0.7 years (range: 3.2\u20135.5 years). Only one patient (1.6%, 0.4%\/year) presented a major extracranial bleeding, and none had cerebral hemorrhage. Six thromboembolic events occurred in five patients (7.9%): three recurrent strokes, two transient ischemic attacks, and one myocardial infarction (2.2%\/year). Over a follow-up period of more than three years, 13 patients discontinued edoxaban (20.6%). Conclusions: Edoxaban seems to be effective and safe in the long-term. The persistence rate of edoxaban therapy is optimal after more than three years of treatment.<\/jats:p>","DOI":"10.3390\/brainsci13111541","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T02:05:07Z","timestamp":1698890707000},"page":"1541","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2370-840X","authenticated-orcid":false,"given":"Irene","family":"Scala","sequence":"first","affiliation":[{"name":"School of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy"},{"name":"Department of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Bellavia","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5698-2336","authenticated-orcid":false,"given":"Pier Andrea","family":"Rizzo","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Di Giovanni","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Monforte","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Morosetti","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-799X","authenticated-orcid":false,"given":"Giacomo Della","family":"Marca","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy"},{"name":"Department of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-3916","authenticated-orcid":false,"given":"Fabio","family":"Pilato","sequence":"additional","affiliation":[{"name":"Neurology, Neurophysiology and Neurobiology Unit, Department of Medicine, Fondazione Campus Bio-Medico di Roma, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-9271","authenticated-orcid":false,"given":"Aldobrando","family":"Broccolini","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy"},{"name":"Department of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Profice","sequence":"additional","affiliation":[{"name":"UOC Neurologia and Stroke Unit, Mater Olbia Hospital, 07026 Olbia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-6594","authenticated-orcid":false,"given":"Giovanni","family":"Frisullo","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/CIRCRESAHA.116.308413","article-title":"Global Burden of Stroke","volume":"120","author":"Feigin","year":"2017","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tcm.2021.12.001","article-title":"Atrial fibrillation and stroke: A review and new insights","volume":"33","author":"Segura","year":"2023","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/svn-2018-000143","article-title":"Cardioembolic stroke: Everything has changed","volume":"3","author":"Spence","year":"2018","journal-title":"Stroke Vasc. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"ref_7","unstructured":"U.S. Food and Drug Administration\u2014Center for Drug Evaluation and Research (2023, July 14). SAVAYSA 15, 30, and 60 mg Tablets NDA 206316\/Original 1 Approval Letter, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206316orig1orig2s000toc.cfm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00415-021-10866-2","article-title":"Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: Results of the prospective multicenter Berlin Atrial Fibrillation Registry","volume":"269","author":"Tutuncu","year":"2022","journal-title":"J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/bcp.14029","article-title":"Appropriateness of prescription of oral anticoagulant therapy in acutely hospitalized older people with atrial fibrillation. Secondary analysis of the SIM-AF cluster randomized clinical trial","volume":"85","author":"Antoniazzi","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Frisullo, G., Profice, P., Brunetti, V., Scala, I., Bellavia, S., Broccolini, A., Caliandro, P., Di Iorio, R., Morosetti, R., and Pilato, F. (2021). Prospective Observational Study of Safety of Early Treatment with Edoxaban in Patients with Ischemic Stroke and Atrial Fibrillation (SATES Study). Brain Sci., 11.","DOI":"10.3390\/brainsci11010030"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(00)02237-6","article-title":"Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score","volume":"355","author":"Barber","year":"2000","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1161\/STROKEAHA.107.511162","article-title":"Extent of hypoattenuation on CT angiography source images predicts functional outcome in patients with basilar artery occlusion","volume":"39","author":"Puetz","year":"2008","journal-title":"Stroke"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2018.05.066","article-title":"Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety","volume":"72","author":"Lee","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"De Caterina, R., Kim, Y.H., Koretsune, Y., Wang, C.C., Yamashita, T., Chen, C., Reimitz, P.E., Unverdorben, M., and Kirchhof, P. (2021). Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040573"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1125576","DOI":"10.3389\/fphar.2023.1125576","article-title":"Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study","volume":"14","author":"Grymonprez","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial","volume":"5","author":"Kato","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/bcp.14264","article-title":"Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions","volume":"86","author":"Zhang","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e007943","DOI":"10.1161\/JAHA.117.007943","article-title":"Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation","volume":"7","author":"Sandesara","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2021.03.003","article-title":"Patients\u2019 adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants","volume":"333","author":"Barcellona","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"994085","DOI":"10.3389\/fcvm.2022.994085","article-title":"Adherence and persistence to oral anticoagulants in patients with atrial fibrillation: A Belgian nationwide cohort study","volume":"9","author":"Grymonprez","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jcph.2204","article-title":"Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5-Year Retrospective Cohort Study","volume":"63","author":"Aigami","year":"2023","journal-title":"J. Clin. Pharmacol."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/11\/1541\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:15:51Z","timestamp":1760130951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/13\/11\/1541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["brainsci13111541"],"URL":"https:\/\/doi.org\/10.3390\/brainsci13111541","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}